In general, caution should be exercised in the administration of lamivudine and zidovudine tablet in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy Lamivudine and zidovudine tablet is not recommended for patients with creatinine clearance less than 50 mL per min because lamivudine and zidovudine tablet is a fixed-dose combination and the dosage of the individual components cannot be adjusted. Zidovudine is primarily eliminated by hepatic metabolism and zidovudine concentrations are increased in patients with impaired hepatic function, which may increase the risk of hematologic toxicity. Manufacturer makes no recommendation. Updated June 19, 2020 Other studies have demonstrated no significant interaction between lamivudine and zidovudine or between lamivudine and interferon-alpha-2b.

Be ready to tell or show what was Due to inconsistencies between the drug labels on DailyMed and the pill images provided by Lamivudine has the following interaction information: Amiodarone. advice about side effects. It is taken by mouth twice a day. Safety and efficacy of lamivudine have not been established for treatment of chronic hepatitis B in subjects dually infected with HIV-1 and HBV. Instruct patients that if they miss a dose, they should take it as soon as they remember. (•Agents antagonistic with zidovudine: Concomitant use should be avoided (Lamivudine and Zidovudine tablet, USP a combination of two nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. A total of 1,816 HIV-1-infected adults with 25 to 250 (median 122) CD4 cells per mm The utility of zidovudine alone for the prevention of maternal-fetal HIV-1 transmission was demonstrated in a randomized, double-blind, placebo-controlled trial conducted in  HIV-1-infected pregnant women with CD4+ cell counts of 200 to 1,818 cells per mm Lamivudine and Zidovudine Tablets, USP containing 150 mg lamivudine and 300 mg zidovudine, are white, film coated, capsule shaped tablets debossed with 'H' and score line on one side and '2' on other side.

Liquid and solid oral formulations of the individual components of lamivudine and zidovudine tablet are available for these populations.Lamivudine and Zidovudine tablets, USP contain 150 mg lamivudine, USP and 300 mg   zidovudine, USP are white, film coated, capsule shaped tablets debossed with 'H' and score line on one side and '2' on other side.Lamivudine and Zidovudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine. 68788-7298-9 Inform patients that sustained decreases in plasma HIV-1 RNA have been associated with a reduced risk of progression to AIDS and death. CAESAR was a multi-center, double-blind, placebo-controlled trial comparing continued current therapy (zidovudine alone [62% of subjects] or zidovudine with didanosine or zalcitabine [38% of subjects]) to the addition of lamivudine or lamivudine plus an investigational non-nucleoside reverse transcriptase inhibitor, randomized 1:2:1.

Results are summarized in Table 5. Patients should be regularly assessed for signs of lipoatrophy during therapy with zidovudine-containing products, and if feasible, therapy should be switched to an alternative regimen if there is suspicion of lipoatrophy. Reproduction studies have been performed in rats and rabbits at orally administered doses up to 4,000 mg per kg per day and 1,000 mg per kg per day, respectively, producing plasma levels up to approximately 35 times that for the adult HIV dose. Both lamivudine and bortezomib can increase the risk of peripheral neuropathy. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. help if any of these side effects or any other side effects bother you or do not go away: The mechanism and long-term consequences of these events are currently unknown. If a dose reduction of the lamivudine or zidovudine components of lamivudine and zidovudine tablet is required for patients with renal impairment then the individual components should be usedLamivudine and zidovudine tablet is a fixed-dose combination and the dosage of the individual components cannot be adjusted.

Advise patients not to share personal items that can have blood or body fluids on them, like toothbrushes and razor blades. Lamivudine and zidovudine are antiviral medications that prevent human immunodeficiency virus from multiplying in your body. Select one or more newsletters to continue. Lamivudine (3tc) (Epivir; Epivir HBV) is a drug prescribed for the treatment of HIV infection and hepatitis B infection. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.Acute overdoses of zidovudine have been reported in pediatric patients and adults. Treatment with lamivudine and zidovudine tablet should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity, which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations. Lamivudine is cleared renally. 68788-7298-3, Frequent monitoring of hematologic toxicities is advised.There is no known specific treatment for overdose with lamivudine and zidovudine tablet. (Tablets: Scored 150 mg lamivudine and 300 mg zidovudine (Lamivudine and Zidovudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine.